Loading
Doxycycline · Regulatory label update
U.S. Food and Drug Administration · August 11, 2026
An action by a regulator. Authoritative on labelling and availability.
This record documents FDA supplemental approval of a labeling change for doxycycline hyclate 100 mg capsules (Amneal Pharmaceuticals) effective 11 August 2026. The record contains no clinical trial data, efficacy results, or safety findings; it is solely a regulatory action permitting updated product labeling.
Regulatory label update.
This record documents FDA supplemental approval of a labeling change for doxycycline hyclate 100 mg capsules (Amneal Pharmaceuticals) effective 11 August 2026. The record contains no clinical trial data, efficacy results, or safety findings; it is solely a regulatory action permitting updated product labeling.
This regulatory record does not contain clinical trial results, efficacy data, or safety findings. No comparative benefit or adverse event data are reported.
The source did not state who this applies to in practice.
This is an FDA supplemental approval action for doxycycline hyclate labeling; it documents a regulatory decision, not clinical trial evidence or efficacy data.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Drugs@FDA record for application ANDA207289. This is a regulatory action record, not a clinical study. Brand name: DOXYCYCLINE HYCLATE. Active ingredient: DOXYCYCLINE. Sponsor: AMNEAL PHARMS. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-08-11. Products: DOXYCYCLINE HYCLATE, CAPSULE, ORAL, DOXYCYCLINE HYCLATE EQ 100MG BASE.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.